ROR1 and ROR2—novel targets for neuroblastoma

References

• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–2120. doi: 10.1016/S0140-6736(07)60983-0.
   PubMed Web of Science ®Google Scholar
• Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60(6):985–993. doi: 10.1002/pbc.24433.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi: 10.1056/NEJMoa0911123.
   PubMed Web of Science ®Google Scholar
• Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9(3):247–256. doi: 10.1016/S1470-2045(08)70069-X.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27(7):1007–1013. doi: 10.1200/JCO.2007.13.8925.
   PubMed Web of Science ®Google Scholar
• Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem. 1992;267(36):26181–26190.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639–1647. doi: 10.1084/jem.194.11.1639.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625–1638. doi: 10.1084/jem.194.11.1625.
   PubMed Web of Science ®Google Scholar
• Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396–404. doi: 10.1158/1078-0432.CCR-07-1823.
   PubMed Web of Science ®Google Scholar
• Yu J, Chen L, Cui B, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest. 2016;126(2):585–598. doi: 10.1172/JCI83535.
   PubMed Web of Science ®Google Scholar
• Dave H, Anver MR, Butcher DO, et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One. 2012;7(12):e52655. doi: 10.1371/journal.pone.0052655.
   PubMed Web of Science ®Google Scholar
• Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs. 2012;4(3):349–361. doi: 10.4161/mabs.19870.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen L, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7(3):e31127doi: 10.1371/journal.pone.0031127.
   PubMed Web of Science ®Google Scholar
• Huang X, Park H, Greene J, et al. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS One. 2015;10(7):e0133152doi: 10.1371/journal.pone.0133152.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cui B, Lai H, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci USA. 2014;111(48):17266–17271. doi: 10.1073/pnas.1419599111.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21(3):348–361. doi: 10.1016/j.ccr.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Goodpaster T, Randolph-Habecker J, et al. Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res. 2017;23(12):3061–3071. doi: 10.1158/1078-0432.CCR-16-2083.
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol. 2005;7(6):591–600. doi: 10.1038/ncb1258.
   PubMed Web of Science ®Google Scholar
• Tyner JW, Deininger MW, Loriaux MM, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 2009;106(21):8695–8700. doi: 10.1073/pnas.0903233106.
   PubMed Web of Science ®Google Scholar
• Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 2013;73(12):3649–3660. doi: 10.1158/0008-5472.CAN-12-3832.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang H, Chen T, et al. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma. PLoS One. 2015;10(5):e0127092doi: 10.1371/journal.pone.0127092.
   PubMed Web of Science ®Google Scholar
• Chien HP, Ueng SH, Chen SC, et al. Expression of ROR1 has prognostic significance in triple negative breast cancer. Virchows Arch. 2016;468(5):589–595. doi: 10.1007/s00428-016-1911-3.
   PubMed Web of Science ®Google Scholar
• Zhang H, Qiu J, Ye C, et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 2015;4(1):5811. doi: 10.1038/srep05811.
   Google Scholar
• Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Transl Lung Cancer Res 2014;3(3):122–130.
   PubMedGoogle Scholar
• Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006;98(17):1193–1203. doi: 10.1093/jnci/djj330.
   PubMedGoogle Scholar
• Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One. 2011;6(6):e21018. doi: 10.1371/journal.pone.0021018.
   PubMed Web of Science ®Google Scholar
• Choi MY, Widhopf GF, 2nd, Ghia EM, et al. Phase I Trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell. 2018;22(6):951–959 e953. doi: 10.1016/j.stem.2018.05.018.
   PubMed Web of Science ®Google Scholar
• Henry C, Llamosas E, Knipprath-Meszaros A, et al. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget 2015;6(37):40310–40326. doi: 10.18632/oncotarget.5643.
   PubMedGoogle Scholar
• Modak S, Le Luduec JB, Cheung IY, et al. Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study. Oncoimmunology 2018;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305.
   PubMed Web of Science ®Google Scholar